PCM
AMED

Prelude Capital Management’s Amedisys AMED Stock Holding History

Prelude Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,700
Closed -$2.51M – 1171
2024
Q4 		$2.51M Buy
+27,700
New +$2.54M 0.16% 135
2024
Q3 		– Sell
-4,200
Closed -$386K – 1258
2024
Q2 		$386K Buy
+4,200
New +$390K 0.03% 664
2022
Q2 		– Sell
-5,200
Closed -$896K – 1803
2022
Q1 		$896K Hold
5,200
– – 0.03% 635
2021
Q4 		$842K Buy
5,200
+1,600
+44% +$257K 0.02% 701
2021
Q3 		$537K Buy
+3,600
New +$748K 0.01% 856
2014
Q2 		– Sell
-1,000
Closed -$15K – 1883
2014
Q1 		$15K Buy
+1,000
New +$15.4K ﹤0.01% 1729

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's AMED Position: Q3 2025 in Review

Prelude Capital Management sold out of Amedisys (AMED) in Q3 2025, closing a stake of 90,361 shares — an estimated $8.89M sold.

Prelude Capital Management first reported a position in AMED in Q3 2013 and held it in 29 quarters. The position peaked at $8.89M in Q2 2025. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Prelude Capital Management reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 90,361 Amedisys shares in Q3 2025, an estimated $8.89M.
  • Prelude Capital Management first reported a position in Amedisys in Q3 2013 and held it in 29 quarters.
  • Prelude Capital Management's Amedisys position peaked at $8.89M in Q2 2025.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.